Search research articles
Contact Us
Filters
Showing results (71-80 of 96) with videos related to
Page
of 10
Sort By:
The American Journal of Surgical Pathology
|
February 22, 2026
International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions: Working Group 4 Precursor Lesions of Testis Results of a Premeeting Survey
Felix Bremmer, Maurizio Colecchia, Katrina Collins, et al.
The Journal of Urology
|
April 9, 2025
Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial
Brian Hu, Muhannad Alsyouf, Ala'a Farkouh, et al.
JCO Precision Oncology
|
May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
The Oncologist
|
November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
Laura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
JCO Precision Oncology
|
March 2, 2026
Erratum: Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors
Rebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
JCO Precision Oncology
|
September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors
Rebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2023
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study
Luca Antonelli, Davide Ardizzone, Praful Ravi, et al.
The Prostate
|
November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
Christopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
Radiology
|
August 20, 2024
Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial)
Phillip H Kuo, Michael J Morris, Jacob Hesterman, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 96) with videos related to
Sort By:
Page
of 10
The American Journal of Surgical Pathology
|
February 22, 2026
International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions: Working Group 4 Precursor Lesions of Testis Results of a Premeeting Survey
Felix Bremmer, Maurizio Colecchia, Katrina Collins, et al.
The Journal of Urology
|
April 9, 2025
Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial
Brian Hu, Muhannad Alsyouf, Ala'a Farkouh, et al.
JCO Precision Oncology
|
May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
The Oncologist
|
November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
Laura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
JCO Precision Oncology
|
March 2, 2026
Erratum: Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors
Rebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
JCO Precision Oncology
|
September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors
Rebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2023
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study
Luca Antonelli, Davide Ardizzone, Praful Ravi, et al.
The Prostate
|
November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
Christopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
Radiology
|
August 20, 2024
Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial)
Phillip H Kuo, Michael J Morris, Jacob Hesterman, et al.
Page
of 10